Enantiomer selective action on neurotransmission
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsThomas J. Montine, Adam Wawro
Life of this patent
Estimating the term…
Abstract
Methods of use, pharmaceutical formulations, and labeled versions of compounds are provided of compounds that penetrate the blood-brain barrier and influence the balance of excitatory versus inhibitory neurotransmission by enantiomer selective modulation of glutamate and GABA metabolism. In some embodiments, a glutamatergic false neurotransmitter is S-2-methylglutamate (S-2MeGlu). In some embodiments a GABAergic false neurotransmitters is R-4 aminopentanomic acid (4APA) or S-4 aminopentanomic acid (S-4APA), with high penetration of the blood brain barrier and low toxicity, therein providing useful pharmacologic or imaging agents.
Claims15
A method of altering balance of excitatory to inhibitory neurotransmission by a method comprising:
- administering an effective dose of an agent that provides enantiomeric selective metabolism modulation in the GABA shunt or glutamate-glutamine cycle.
Dependencies are inferred from the claim text.